Skip to Content
Biotechnology

Blood plasma taken from covid-19 survivors might help patients fight off the disease

A small study from China suggests transfusions of blood from those who have beaten the disease could help buy time for new victims
AP

Transfusions of blood serum from people who’ve recovered from covid-19 could help severe cases recover, according to a new study from China.

Plasma donation: The concept of using blood from survivors—or “convalescent plasma”—isn’t new, but it’s now being tried against covid-19 because there aren’t any drugs known to work. A survivor’s blood is charged up with antibodies against the virus. Give these to someone else, and they can give a temporary assist by interfering with the virus until that person mounts an immune response. 

You can read all our coverage of the coronavirus/covid-19 outbreak for free, and also sign up for our coronavirus newsletter. But please consider subscribing to support our nonprofit journalism.

Positive result: The Chinese study, authored by scientists working for state-owned Sinopharm, wasn’t randomized, so benefits from plasma aren’t proven with certainty. But the 10 severely affected patients they treated with a half a Coke can’s worth of plasma seemed to do much better after three days.  In several of the patients the virus cleared up entirely, leading the authors to conclude that plasma “can serve as a promising rescue option” for severe covid-19 cases. The report follows a previous one from China involving five patients.

Recruiting now: US hospitals have been scrambling to find blood donors and are starting to try plasma transfusions, too. The American Association of Blood Banks has set up a web page so people recovered from covid-19 can find out where to donate blood. So has the Red Cross. People must be “fully recovered” to donate. The US Food and Drug Administration says people should wait 14 days after symptoms to donate.

Deep Dive

Biotechnology

These scientists used CRISPR to put an alligator gene into catfish

The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.

Next up for CRISPR: Gene editing for the masses?

Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.

CRISPR for high cholesterol: 10 Breakthrough Technologies 2023

New forms of the gene-editing tool could enable treatments for common diseases.

An ALS patient set a record for communicating via a brain implant: 62 words per minute

Brain interfaces could let paralyzed people speak at almost normal speeds.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.